Proteomics Internationals PromarkerD Diagnostic Test Validated by EU

Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) announces the publication today of the data underpinning it PromarkerD Diagnostic test for diabetic kidney disease. The publication follows an independent review and provides an important verification of the test and its global applicability. The study has been published in the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).

KEY TAKEAWAYS:

• The journal article proves the efficacy of the process used to develop and test PILL’s PromarkerD protein ‘fingerprint’ that detects the onset of kidney disease in patients with diabetes;
• More than 500,000 Australians will have diabetic kidney disease by 2040, with dialysis already costing more than $100,000 per person per year;
• Globally the diabetes epidemic cost health systems $673 billion dollars in 2015;
• Today there are 234 million people living with diabetes in China, India, the USA, Brazil and Russia alone, according to the International Diabetes Federation;
• Worldwide this number is forecast to rise to 642 million people by 2040, and 214 million people are predicted to get chronic kidney disease as a result.

“If we can stem this health crisis tsunami by identifying and treating people before they are symptomatic we are saving lives, as well as billions of dollars in health costs,” said Dr Richard Lipscombe, PILL’s managing director.

PILL is at the forefront of using proteomics technology to diagnose disease worldwide, and has already been granted patents for PromarkerD in Australia, China, Russia and the USA.

Dr Lipscombe said publication of PILL’s diagnostics platform technique that uses proteins to detect disease represented an important validation step and followed evaluation by independent scientific experts. “Going through the peer review process in this way means our method is independently verified,” he said.

“We welcome the high level of scrutiny that comes with the publication process and are delighted to announce yet another endorsement of our diagnostic platform. It helps puts our work in front of global licence partners, as we commercialise PromarkerD.”

PILL (ASX: PIQ) is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

Request Information